Factors influencing the cost include the specific type of peptide, the required dosage, and the overall complexity of your treatment plan
insulin glargine, insulin degludec or a GLP1R agonist (GLP1Ra) (SURPASS program: NCT03861039, NCT03861052, NCT03954834, NCT04039503, NCT04093752, NCT03987919, NCT03730662, NCT03882970) and in obese but not diabetic patients (SURMOUNT-1, NCT04184622)
Those results were significantly better than those experienced by the group treated with placebo injections (n = 28)
10.3389/fphar.2019.01022 Front Pharmacol
Brand-name Semaglutide (Wegovy) carries a high retail price, and insurance coverage remains inconsistent
Understanding the evidence, knowing who should exercise caution, and recognising when to seek medical advice are essential for informed decision-making about GLP-1 therapy